PTC Therapeutics Dirección
Dirección controles de criterios 2/4
El CEO de PTC Therapeutics es Matt Klein , nombrado en Mar 2023, tiene una permanencia de 1.67 años. compensación anual total es $8.94M, compuesta por 8.4% salario y 91.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.068% de las acciones de la empresa, por valor de $2.41M. La antigüedad media del equipo directivo y de la junta directiva es de 5.7 años y 9.4 años, respectivamente.
Información clave
Matt Klein
Chief Executive Officer (CEO)
US$8.9m
Compensación total
| Porcentaje del salario del CEO | 8.4% |
| Permanencia del CEO | 1.7yrs |
| Participación del CEO | 0.07% |
| Permanencia media de la dirección | 5.7yrs |
| Promedio de permanencia en la Junta Directiva | 9.4yrs |
Actualizaciones recientes de la dirección
Recent updates
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Fly 29% But Investors Aren't Buying For Growth
Oct 09
PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value
Sep 12Little Excitement Around PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Revenues
Jun 28PTC Therapeutics: Riding The Regulatory Rollercoaster With Translarna
May 22Industry Analysts Just Upgraded Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Revenue Forecasts By 11%
May 22PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts
May 14PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Mar 03PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options
Feb 11An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued
Jun 23Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price
May 18An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued
Mar 02PTC pauses enrollment in mid-stage study for Huntington's disease candidate in U.S.
Oct 19PTC Therapeutics betas topline expectations, strengthens commercial portfolio
Aug 05PTC Therapeutics gene therapy Upstaza wins approval in EU for ultra-rare neuromuscular disorder
Jul 20Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$453m |
| Jun 30 2024 | n/a | n/a | -US$480m |
| Mar 31 2024 | n/a | n/a | -US$579m |
| Dec 31 2023 | US$9m | US$747k | -US$627m |
| Sep 30 2023 | n/a | n/a | -US$642m |
| Jun 30 2023 | n/a | n/a | -US$618m |
| Mar 31 2023 | n/a | n/a | -US$571m |
| Dec 31 2022 | US$5m | US$598k | -US$559m |
Compensación vs. Mercado: La compensación total de Matt($USD8.94M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD6.54M).
Compensación vs. Ingresos: La compensación de Matt ha aumentado mientras la empresa no es rentable.
CEO
Matt Klein (52 yo)
1.7yrs
Permanencia
US$8,937,025
Compensación
Dr. Matthew B. Klein, also known as Matt, M.D., MS, FACS, serves as Chief Executive Officer and Director of PTC Therapeutics, Inc. since March 24, 2023He served as an Independent Director at ClearPoint Neu...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 1.7yrs | US$8.94m | 0.068% $ 2.4m | |
| Co-Founder | 26.8yrs | US$5.66m | sin datos | |
| Co-Founder | 26.8yrs | US$511.98k | 0.016% $ 568.1k | |
| Chief Financial Officer | 1.3yrs | US$3.01m | 0.015% $ 549.0k | |
| Executive VP & Chief Legal Officer | 12.7yrs | US$2.19m | 0.063% $ 2.2m | |
| Chief Business Officer | 9.6yrs | US$2.41m | 0.026% $ 907.7k | |
| Executive VP & Chief Medical Officer | 4.5yrs | US$2.39m | 0.019% $ 684.2k | |
| Senior VP | 5.4yrs | US$1.70m | 0.022% $ 784.6k | |
| Chief Technical Operations Officer | 5.9yrs | US$2.67m | 0.054% $ 1.9m | |
| Senior VP & Chief Information Officer | less than a year | sin datos | sin datos | |
| Investor Relations Officer | no data | sin datos | sin datos | |
| Vice President of Corporate Communications | no data | sin datos | sin datos |
5.7yrs
Permanencia media
57yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de PTCT es experimentado (5.7 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 1.7yrs | US$8.94m | 0.068% $ 2.4m | |
| Co-Founder | 1.7yrs | US$5.66m | sin datos | |
| Co-Founder | 26.8yrs | US$511.98k | 0.016% $ 568.1k | |
| Independent Chairman of the Board | 23.3yrs | US$816.96k | 1.95% $ 69.1m | |
| Independent Director | 18.9yrs | US$438.98k | 0.014% $ 483.0k | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 5.9yrs | US$441.98k | 0.0093% $ 331.4k | |
| Member of Scientific Advisory Board | 21yrs | sin datos | sin datos | |
| Independent Director | 9.4yrs | US$426.98k | 0.014% $ 483.0k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 5.9yrs | US$421.98k | 0.0076% $ 270.0k |
9.4yrs
Permanencia media
64yo
Promedio de edad
Junta con experiencia: La junta directiva de PTCT se considera experimentada (9.4 años de antigüedad promedio).